Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. - Wikidata - awgldk - TriplyDB

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo.

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo.

http://www.wikidata.org/entity/Q33774353

about

PI3K and AKT: Unfaithful Partners in Cancer Cutting through the complexities of mTOR for the treatment of stroke Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acid on phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells.Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.Branched chain amino acid suppresses hepatocellular cancer stem cells through the activation of mammalian target of rapamycin Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer.Expression and clinical significance of mammalian target of rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue.Endometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by Epigenetics Mammalian target of rapamycin signaling in diabetic cardiovascular disease Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2 OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives mTOR pathway in colorectal cancer: an update.Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity Biliverdin's regulation of reactive oxygen species signalling leads to potent inhibition of proliferative and angiogenic pathways in head and neck cancer.Targeting autophagy during cancer therapy to improve clinical outcomes.Translation initiation in colorectal cancer.Carcinogenic mechanisms of endometrial cancer: involvement of genetics and epigenetics.Mesoglycan attenuates VSMC proliferation through activation of AMP-activated protein kinase and mTOR.Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle Potential therapeutic effects of mTOR inhibition in atherosclerosis.Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells.mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis.Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.An in silico protocol for identifying mTOR inhibitors from natural products.Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.Overexpression of Rictor protein in colorectal cancer is correlated with tumor progression and prognosis.Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma.Tounong Powder () extracts induce G1 cell cycle arrest and apoptosis in LoVo cells.

P2860

Q26781367-14B996F5-B242-4E76-8888-E125083CC622 Q26851291-CCB3BC18-40C1-480B-9EF7-0E86ADA8A94E Q33798469-C9721973-42B1-43EB-A985-3D9B0A64A62A Q34188530-CD373021-A30E-476F-BE0F-99FE7C7DA1EC Q34377965-B40A1CB4-F7EF-4D8D-BF26-41AD18AA3E3B Q34852951-DEE8BF54-B087-4C53-ACCB-1DC3212F3FE3 Q35003274-D033EA1D-F75A-40F4-9BF1-525020288A37 Q35005636-E27B5D19-FC16-475C-BBD2-1FDBD7736871 Q35060898-58042B5E-D0BD-4DAE-BE4D-C37C7CAD2B6E Q35157985-8C80A830-E4A8-49EC-932C-2513D140D9DC Q35631301-A0B485E1-6568-4D1D-93C6-6E556EB99EEE Q35662372-FC49E404-3224-4056-A08D-9045B566875A Q35740111-19221CD7-CDD4-4F2F-8D04-280CA08FE815 Q35803677-A2610E4B-9A94-4CF2-B749-810AB466088F Q35882785-8D847899-354E-41DD-B912-8BE71079B8DF Q36100715-B4FBDEE2-A5C9-4283-877F-65BAE4EBC241 Q36118888-B41D0636-EBE4-4329-AD70-55E4EF1C15E7 Q36413415-AB46D958-B6F3-4590-AA91-E4D6D71F38C1 Q36414487-AB1090E7-8E48-4A62-98D6-19567367A399 Q36788720-31E3088C-09E0-4C53-AF48-EE90E744EEA4 Q37132788-5311AC72-EB93-41A7-9937-D9C60FB314D6 Q37649634-BB886153-9145-4CA4-9E60-D340968F47E4 Q37661161-8E459C92-6AAF-4176-9498-93A414F02A7C Q37711699-DE1B10A9-0EB7-4E20-AB8C-10B624D21561 Q37858077-C23667CC-CF36-4FD4-A09E-9EF3D0911395 Q37993753-6692B520-B588-4ABA-A8AC-172EAD0C8A3F Q38240724-38C1C514-20A3-4FE0-9E00-526DB9C72C51 Q38368556-4532AA5C-BBD0-4C30-8EE4-70CADF59B088 Q38612967-E664F3D1-10BD-405B-B791-749CF3443F72 Q38628797-A86C1F13-2DD5-44E7-A21B-2B482C7344E0 Q39188495-DC410D3B-8E04-46DB-BB91-B36B25161DB5 Q39210322-7CE5768F-7EC9-4E4A-939E-797B30CF49DE Q39605943-D3ADFD0F-E0E1-4D6F-826D-4314C0AAEC71 Q39680127-BC315785-9433-43A8-A57A-B89A135181B0 Q41781449-3C50CA36-AE42-4BE6-9732-8DFE89B8540C Q42197995-9A341056-CDF0-4D04-8C63-3CAFD2B9CAE7 Q45778366-6932F73C-5F1A-4955-88E3-DB3F58EB78E2 Q47429788-D0745F87-154B-472F-A4AC-47D2E01FED8B Q50136364-29CFDE7C-0888-4281-899D-F25D3272F115 Q51673030-7CD2D58E-B207-441F-A81F-DDFD7DAEF55B

P2860

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo.

http://www.wikidata.org/entity/Q33774353

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeting mTORC2 inhibits colo ...... o and tumor formation in vivo.

@ast

Targeting mTORC2 inhibits colo ...... o and tumor formation in vivo.

@en

type

label

Targeting mTORC2 inhibits colo ...... o and tumor formation in vivo.

@ast

Targeting mTORC2 inhibits colo ...... o and tumor formation in vivo.

@en

prefLabel

Targeting mTORC2 inhibits colo ...... o and tumor formation in vivo.

@ast

Targeting mTORC2 inhibits colo ...... o and tumor formation in vivo.

@en

P1433

Q33774353-75E3F1D0-5317-4E74-A992-3C1990ABF586

P1476

Q33774353-C3FBB789-EF5D-4F7A-A8D1-25CBDB05AF36

P2093

Q33774353-2137AA47-ECC3-4BBA-BC3E-AD951841A07A

Q33774353-A4365A59-2F54-4B22-A2E9-A898E8BAA3E4

Q33774353-AB8E6C45-71E1-4704-8747-493420FC8E0E

Q33774353-F23D3DD0-2AF8-48D5-8527-E6AE0A15B691

Q33774353-FE6B0551-71F2-4361-85CB-D5A3EBEBE045

P2860

Q33774353-0027C76B-5334-4F10-A488-C216436627D2

Q33774353-10ED6AF7-61F0-4B85-ADEE-350BF79C3DF1

Q33774353-193DEA22-7865-4546-841E-63EF6920C0D1

Q33774353-253F0118-AA42-4255-A5ED-D276C8223703

Q33774353-2F83B196-DD41-4D3D-A2ED-36BEB206A2AC

Q33774353-30779D10-6100-493F-B398-8CAC960D81AC

Q33774353-4AD06287-1A9E-449C-8708-2BCC37227DAF

Q33774353-737F5CBD-8CB4-49C0-801E-C60209B4DA75

Q33774353-761423B0-5B6E-4BB5-84FB-3334BDA48B77

Q33774353-83553847-F74A-4C44-B3D3-21B5B82C69BE

P2888

Q33774353-2EAF0131-F06A-4E46-9664-C1FEF84C088B

P304

Q33774353-C25DB41B-289D-4AC8-B934-40CC04161FE7

P31

Q33774353-D7DE2A80-1122-445C-A04C-6E4DF9B951C1

P356

Q33774353-6B2175DF-1F1F-471C-A5D2-66DB41B7EDE4

P478

Q33774353-288EDD80-1922-40CF-812E-584804A52054

P577

Q33774353-FE8FA63A-DD56-405F-81BC-F1B81981526C

P5875

Q33774353-D0C4DED8-7384-449D-A2A9-6D99C9F5F7EB

P6179

Q33774353-3CC48CAE-36C0-4505-AF07-09BEB8B6E9D6

P698

Q33774353-A5E00BFD-5F17-4A07-AC97-5A287E99FB6D

P932

Q33774353-51293E7E-E637-41AA-A9DC-D7E3D0B5882A

P356

P1433

Molecular Cancer

P1476

Targeting mTORC2 inhibits colo ...... o and tumor formation in vivo.

@en

P2093

Anne Dormond-Meuwly

http://www.w3.org/2001/XMLSchema#string

Didier Roulin

http://www.w3.org/2001/XMLSchema#string

Nicolas Demartines

http://www.w3.org/2001/XMLSchema#string

Olivier Dormond

http://www.w3.org/2001/XMLSchema#string

Yannick Cerantola

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

TOR signaling in growth and metabolism

Defining the role of mTOR in cancer

Current development of mTOR inhibitors as anticancer agents

Upstream and downstream of mTOR

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

P2888

P304

57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-9-57

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41941531

http://www.w3.org/2001/XMLSchema#string

P6179

1052162150

http://www.w3.org/2001/XMLSchema#string

P698

20226010

http://www.w3.org/2001/XMLSchema#string

P932

2850884

http://www.w3.org/2001/XMLSchema#string